Daptomycin shortage — CA supply status & alternatives

Daptomycin

ATC J01XX09

🇦🇺 AUST R 300034 · Juno Pharmaceuticals Pty Ltd

In supply · Australia

Pfizer CubicinDaptomicina CiplaDaptomycine Noridem

In supply · 🇦🇺 Australia · short in🇨🇦 CA🇺🇸 US🇬🇷 GR

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Active ingredient (INN)	Daptomycin
Brand names	Pfizer, Cubicin, Daptomicina Cipla, Daptomycine Noridem
ATC level 5	J01XX09
ATC level 4	J01XX
Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper
Controlled substance	No
Marketing-authorisation holders	Juno Pharmaceuticals Pty Ltd, Accord Healthcare Pty Ltd, Dr Reddys Laboratories Australia Pty Ltd, Pfizer Australia Pty Ltd +5 more
Registrations on file	26
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Other markets

🇺🇸 US

US$21.85

Acquisition

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

9 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Low concentration risk

Chongqing Daxin Pharmaceutical CO LTDLivzon Group Fuzhou Fuxing Pharmaceutical CO LTDOlon SPAXellia Pharmaceuticals ApsZhejiang Medicine CO LTDChengdu Yacht Biotechnology CO LTD+3 more

Manufacturing countries: China, Italy, Denmark, South · Source: FDA List of Drug Master Files

Recalls official enforcement reports

🇺🇸

DAPTOMYCIN

Accord Healthcare, Inc. · Feb 2023

Class IIdetails ↗

🇺🇸

DAPTOMYCIN

Accord Healthcare, Inc. · Feb 2023

Class IIdetails ↗

🇺🇸

DAPTOMYCIN

Mylan Institutional LLC · July 2020

Class Idetails ↗

🇺🇸

Daptomycin

Redline Pharmacy Solutions · Feb 2020

Class IIdetails ↗

🇺🇸

Daptomycin

Baptist Health Medical Towers Pharmacy and Infusion Services · Apr 2016

Class IIdetails ↗

Verified timeline regulator events

🇺🇸 30 June 2026

medium reported

🇬🇷 26 June 2026

medium reported

🇬🇷 15 June 2026

medium reported

🇨🇦 16 Mar 2026

high reported

🇦🇺 23 Feb 2026

Shortage resolved

🇦🇺 17 Oct 2025

Shortage resolved

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders26 registrations · 9 MA holders

Product	Strength	Form	Market	MA holder	Status
Juno	500 mg	—	🇦🇺 AU	Juno Pharmaceuticals Pty Ltd	Active
Accord	500 mg	—	🇦🇺 AU	Accord Healthcare Pty Ltd	Active
Reddy'S	500 mg	—	🇦🇺 AU	Dr Reddys Laboratories Australia Pty Ltd	Active
Drla	350 mg	—	🇦🇺 AU	Dr Reddys Laboratories Australia Pty Ltd	Active
Drla	500 mg	—	🇦🇺 AU	Dr Reddys Laboratories Australia Pty Ltd	Active
Dr.Reddy'S	350 mg	—	🇦🇺 AU	Dr Reddys Laboratories Australia Pty Ltd	Active
Dr.Reddy'S	500 mg	—	🇦🇺 AU	Dr Reddys Laboratories Australia Pty Ltd	Active
Rz	350 mg	—	🇦🇺 AU	Dr Reddys Laboratories Australia Pty Ltd	Active
Rz	500 mg	—	🇦🇺 AU	Dr Reddys Laboratories Australia Pty Ltd	Active
Reddy'S	350 mg	—	🇦🇺 AU	Dr Reddys Laboratories Australia Pty Ltd	Active
Pfizer	350 mg	—	🇦🇺 AU	Pfizer Australia Pty Ltd	Active
Pfizer	500 mg	—	🇦🇺 AU	Pfizer Australia Pty Ltd	Active
Wockhardt	500 mg	—	🇦🇺 AU	Wockhardt Bio Pty Ltd	Active
Gh	350 mg	—	🇦🇺 AU	Southern Cross Pharma Pty Ltd	Active
Gh	500 mg	—	🇦🇺 AU	Southern Cross Pharma Pty Ltd	Active

+11 more registrations on file

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.